SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-096648
Filing Date
2024-08-14
Accepted
2024-08-14 07:15:25
Documents
13
Period of Report
2024-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20240814.htm   iXBRL 8-K 43273
2 EX-99.1 virx-ex99_1.htm EX-99.1 150536
3 EX-99.2 virx-ex99_2.htm EX-99.2 54894
  Complete submission text file 0000950170-24-096648.txt   380917

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20240814.xsd EX-101.SCH 23862
16 EXTRACTED XBRL INSTANCE DOCUMENT virx-20240814_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 241204139
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)